CURRICULUM VITAE

NAME: **JULIE ANN TAGUCHI, M.D.**

BUSINESS ADDRESS: Sansum Clinic
317 W. Pueblo Street, Santa Barbara, CA 93105

DATE OF BIRTH: April 4, 1959

BIRTHPLACE: Los Angeles, California

MEDICAL LICENSE: G58135
DEA: BT0580286

BOARD CERTIFIED:

Internal Medicine	1988	
Hematology	1990	recertified in 2001, 2011
Oncology	1991	recertified in 2001, 2011

CURRENT POSITION: Hematology and Oncology Staff Physician
Sansum Clinic
(3/1/93- present)

PAST POSITIONS:

- Staff Physician, Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, California 91010,(818) 359-8111, ext. 2405 (7/91-8/92)
- Urgent Care, Kaiser Foundation Hospital (8/86-91)
- Emergency Room, Kaiser Foundation Hospital (7/88-7/90)

EDUCATION:

College:	Bachelor of Science in Biology, Mount Saint Mary's College, Valedictorian, 1977-1981
Medical School:	University of Southern California, Los Angeles, California, 1981-1985

RESIDENCY: Internal Medicine, Kaiser Foundation Hospital, Los Angeles, California, 1985-1988

FELLOWSHIP:

Oncology:	University of Southern California 1200 North State Street, #4628 Los Angeles, California 90033 1990-1991
Hematology:	Kaiser Foundation Hospital 4867 Sunset Boulevard Los Angeles, California 90027 1988-1990
Recertification:	2011

CLINCAL APPOINTMENTS:

Clinical Assistant Professor of Medicine- University of Southern California- May 2006

HONORS AND AWARDS:

1) College, Valedictorian, MSMC; Summa Cum Laude; Academic Excellence in Biology (1981); President's Award (1981); Saint Catherine's Award (Outstanding Sophomore in Academic and Leadership - 1979); Dean's List (8 Semesters); Who's Who in American Colleges (1980); The National Dean's List (1979-80)
2) Medical School: Outstanding Contribution
3) Residency: Co-Chief Resident
4) Fellowship: Administrative Fellow Award 1991
5) Community Honored Physician- Santa Barbara 2004

CURRENT ORGANIZATIONS AND MEMBERSHIPS:

1) American Society of Clinical Oncology (ASCO);
2) California Medical Association
3) Santa Barbara County Medical Society
4) American College for the Advancement of Medicine
5) Santa Barbara County Medical Society
6) Institute of Functional Medicine

Non-medical
1) Kappa Gamma Pi - International Women's Honor Society;
2) MSMC Women's Leadership Networ
3) Life Chronicles Board member (2013-)

CONFERENCES:

Breast Cancer Resource Center Lecture “Updated Treatment for ER+ Breast Cancer” 2012

“Two Days On Earth” CME sponsored (2008 - 2013)

‘Sex and the Survivor” – 2009-2011 multiple talks throughout United States

“Breast Cancer Update 2008”. ACAM Integrative Oncology Conference
Nov. 18, 2008, Las Vegas, Nevada

“Sex and the Survivor”, Washington Cancer Center October 2007
Santa Barbara City College Adult Education / Schott Center
Breast Cancer Resource Center January 20, 2007
“Sex and the (breast cancer) Survivor”

American College for the Advancement of Medicine conference November 0062
Bio-Identical hormone workshop November1, 2006

1) review of the ACAM –partnered BHRT protocol
2) the Wiley Protocol Experience

Washington Cancer Institute - October 19, 2006
Lecture: “Sex and the Survivor”

Resident Lecture, Cottage Hospital June 2006
“Chemotherapy- up and coming drug therapies”

Resident Lecture, Cottage Hospital June 2005
“MKSAP Oncology Review”

American Association of Orthopedic Medicine Conference - April 21- 24 , 2002
-Workshop: “Nutrition and Healing”
-Lecture: “Cancer and the Musculo-Skeletal System,”

Resident Lecture, Cottage Hospital, Santa Barbara, "CLL" (1/98)
- Tumor Board, Hematology-Oncology Grand Rounds, "Non-Hodgkin's Lymphoma and Rheumatological Diseases" (2/97)
Resident Lecture, Cottage Hospital, Santa Barbara, "Bone Marrow and Blood Morphology" (10/96)
Resident Lecture, Cottage Hospital, Santa Barbara, "Biz, Folate, and Iron Metabolism" (5/96)
Resident Lecture, Cottage Hospital, Santa Barbara, " Anemia" (10/95)
Public Lecture, "Update in Oncology" (9/94)
Residency Program, Cottage Hospital, Santa Barbara, "Introduction into BMT" (4/94)
-Nursing Education, City of Hope, Los Angeles, "GI Complications After Bone Marrow Transplant" (9/92)
Nursing Education - Bone Marrow Transplant Course, City of Hope, Los Angeles, "GI Complications After Bone Marrow Transplant (10/91)
Oncology Grand Rounds, LAC, USC MC, "Ifosfamide and Neurotoxicity" (5/91)
Medical Grand Rounds, Kaiser, Los Angeles, "The CBC Revisited" (7/89)
Hematology Conference, Kaiser, Los Angeles, "Chronic Myelogenous Leukemia" (2/89)
Hematology Conference, Kaiser, Los Angeles, "Polycythemia Rubra Vera" (10/88)
Hematology Conference, Kaiser, Los Angeles, "Candida Hepatitis" (8/88)

GI Conference, Kaiser, Los Angeles, "The Acute Abdomen" (3/88)
Renal Conference, Kaiser, Los Angeles, "Polycystic Kidneys" (1/88)
Hematology Conference, Kaiser, Los Angeles, "Non-Hodgkin's Lymphoma" (1/88)
Medical Grand Rounds - Kaiser LA, "Prophylactic Anticoagulation" (1/87)
Student Grand Rounds LAC - USC, "Crohn's Disease" (1/84)

CLINICAL RESEARCH EXPERIENCE:

2013- present	P.I. for US Oncology Breast Cancer Trials Sansum Clinic
2003-present	GOG Sub-Investigator
2002-present	NCCTG Mayo Affiliate
1998-present	NSABP Sub-Investigator, Santa Barbara, CA
1998-present	SWOG Sub-Investigator, Santa Barbara, CA
1997-present	P.I. for Sansum Clinic Translational Oncology Research Trials
1993-present	CALGB Sub-Investigator, Santa Barbara, CA

RESEARCH ACTIVITIES:

2013 "Randomized phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER@ - positive breast ancer with progressive brain metastases after trastuzumab and/or lapatinib- based therapy: LUX-3"

"Antibody –based Targeting of Breast Cancer Stem Cells"
Poster Session: 2010 California Breast Cancer Research Program
Iskender Teber, Richard Forde, Siobhan Frost, Linc Johnson, Julie
2010 Taguchi, Anne Wallace, Claudia Gottstein

2008 "Anticancer activity of bilberry extract ad component anthocyanins" Journal of Medicinal Food. 2009. George Ayoub, PhD – PI

2007 IRB approval for collection of data for review: BHRT pot breast cancer diagnosis. Unpublished.

2005 P.I. for investigator initiated "bio-identical HRT in perimenopausal women using transdermal compounded estradiol and estriol with progesterone versus control" (not accruing)

2004 Effect of FRS, a liquid vitamin supplement, in patients with metastatic cancer on chemotherapy. A quality of life study- in review

2001 Randomized, Double-Blind Study of Testosterone in Men with BPH with Biopsy Negative Cancer and Elevated PSA (unpublished)

1999 Pilot Study of High Dose Progesterone in Terminal Cancer Patients (unpublished due to uncollected lab data)

1980-1988 Review of Large Cell Lymphomas treated at KFH

1988-1990 Comparison of the methods used for detecting the Lupus Anticoagulant

1988-1990 Ceftazidime versus Pip/Gent in Neutropenic Oncology Patients

1982 USC Cancer Fellowship, Patient Compliance and Chemotherapy Alexandra Levine, M.D.

1979 Tumor Immunology, Summer Fellowship Association Western

University, Department of Energy
Student research grant working with rabbit serum antibodies against leukemia and lymphoma cell lines ultimately transformed to hybridoma work.
Paul I. Terasaki, M.D. and Ron Billings, Ph.D.

ACTIVITIES:

Present	Volunteer Positions: Life Chronicles Board Member YMCA, American Cancer Society, Cancer Center of Santa Barbara, Boy Scouts of America, SB Breast Cancer Resource Center,
Fellowship	MSMC Alumna Board, Big Sister Program, Softball League - Pasadena, Volunteer - Tournament of Roses (Float Committee - South Pasadena)
Residency	MSMC Alumna Board
Medical School	Meta Club President (1981-84)

PUBLICATIONS AND ABSTRACTS:

1) "Incidence of Secondary Malignancies Post-Allogenic BMT in Leukemic and Aplastic Leukemia Patients." Abstract, ASCO (1993)

2) "G-CSF Primed Peripheral Blood Stem Cell Autografts in Patients with Advanced Lymphoid Malignancies." Abstract

3) "Fractionated Total Body Irradiation and High Dose Etoposide as a Preparatory Regimen of Bone Marrow Transplantation for 99 Patients with Acute Leukemia in First Complete Remission." Blood, Vol. 82, No. 9, 1993: pp 2920-2928.

4) "Fluorescence in Situ Hybridization (FISH) confirms the presence of a t(11$_2$, 19) (q23º, p.23.1) in a Patient with Absolute Monocytosis." Applied Cytogenetics 22 (3), 1996.

Cruz M, Gaytan P, Jimenez MM, Taguchi J, **Slovak ML**. Fluorescence in situ hybridization (FISH) confirms the presence of a t(11;19)(q23;p13.1) in a patient presenting with absolute monocytosis. *Applied Cytogenetics* 22(3):95, 1996

6) Sex, Lies, and Menopause, T.S. Wiley, with Julie Taguchi, M.D. and Bent Formby, Ph.D. William Morrow publisher, 2003.

7) “A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity “ ASCO 2006 abstract

8) Suzanne Somers interview included in the books , “Ageless” and “Knockout”.

9) Letter to the Editor. Menopause. 2008

TV APPEARANCES:

Sansum Medical Journal, KEYT-TV, Santa Barbara, "Women's Issues" (6/94)
Paula Zahn's News Hour CNN - September 2, 2003
The Paradigm Shift" – Santa Barbara, CA March 15, 2004
The Paradigm Shift" – Santa Barbara, CA June 17, 2004

A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity

Background: A phase II clinical trial was conducted to study the safety and efficacy of neoadjuvant docetaxel/carboplatin (T/C) with or without trastuzumab (H) in women with stage III breast cancer.

Methods: Forty-eight of 75 planned primary breast cancer patients (T3 or T4, any N, M0), age between 18 and 80 have been enrolled. Four cycles of T (75mg/m2) + C (AUC 6) were given every 3 weeks preoperatively. Patients with HER-2 amplified tumors (FISH +) were randomized to receive either weekly concurrent H or T/C alone preoperatively and T/C plus H postoperatively. Tumors were assessed clinically at baseline and after neoadjuvant therapy. Cardiac assessment consisted of medical history, EKG and LVEF (by echocardiogram or MUGA) at baseline and at the end of neoadjuvant chemotherapy.

Results: Available data from 45 of 48 enrolled patients showed 49% (22 cases) with complete clinical response, with 54.5% being HER-2 (+) (12 cases). Stable disease was seen in one patient who was HER-2 (-) (2.2%). Of 37 with complete pathology verification, 11 (29.7%) showed pathologic complete response (pCR) of the primary tumor with 5 cases being HER-2 (+). Of the 22 HER-2 (+) cases that completed neoadjuvant treatment, 11 received T/C/H and 11 received T/C. pCR was noted in 36.4% of the T/C/H group and 9% of the T/C group. LVEF data is available from 43 patients during the neoadjuvant phase, showing 18.6% (8 cases) with decrease of $\geq$ 10% (5 patients in the T/C arm and 3 patients in the T/C/H arm), although none had cardiac symptoms or LVEF below the normal limit.

Conclusions: T/C $\pm$ H is clinically active in patients with locally advanced breast cancer including a 30% pCR rate. The cardiotoxicity rates were comparable between patients who received T/C and T/C/H.

Authors: H. R. Chang, D. Slamon, R. Prati, J. Glaspy, M. Pegram, F. Kass, L. Bosserman, J. Taguchi, R. Dichmann, D. Chung; David Geffen School of Medicine at UCLA, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA

Antibody–based targeting of breast cancer

I. Teber[1], L. Mezei[1], P. Sabo, S. Rajauria, S. Frost, J. Taguchi, A. Wallace, A. Cleland, C. Gottstein
University of California Santa Barbara, California NanoSystems Institute and Department of Physics
University of Washington, Department of Genome Sciences
Sansum Clinic Santa Barbara, Department of Hematology and Oncology
University of California San Diego, Department of Surgery and Breast Care Unit

[1] contributed equally

Antibodies and antibody-drug conjugates are increasingly used in breast cancer therapy, since they enable precise drug delivery, which should result in better efficacy and reduced side effects. A

limiting factor is the availability of specific antibodies against breast cancer cells. We have initiated a study to develop a panel of antibodies suitable for targeting of drugs to breast cancer.
From a pharmacological point of view, it would be highly preferable if only a small subset of cancer cells needed to be targeted. Cancer stem cells are such a small subpopulation and are thought to be critical for breast cancer growth, metastasis and recurrence. However, the fact that they are rare imposes technical hurdles that cannot be approached with conventional reagents and technologies. During our last funding period, we have developed the reagents for the discovery of new specific antibodies against breast cancer cells: 40 breast cancer survivors from Santa Barbara and San Diego area donated blood samples, from which we cloned the antibodies from their secondary immune response. The resulting antibody library has a completely new design, and is technically advanced over existing libraries. In our first experiments we have selected the library, in comparison with conventional libraries, against purified proteins and against MCF-7 breast cancer cells. We have used conventional screening technologies (flow cytometry, enzyme linked immunosorbent assay/ELISA) and next generation sequencing (NGS) to discover antibodies of interest from the pools after selection. The new library was superior to commercial libraries with respect to number of recovered clones and number of binding clones in ELISA. NGS identified several antibody fragments that were enriched after three rounds of selection. We are now in the process to develop a microfluidic chip for separation of primary breast cancer stem cells from patient material, and for selection of antibodies that bind to these cells. We plan to develop the specific antibodies evolving from these selections together with one of the leading pharmaceutical companies in the field into antibody-drug conjugates against breast cancer stem cells. The long term goal is the development of therapies to improve chances of complete remission and to prevent recurrence of breast cancer.

San Antonio Breast Conference 2014:

Title: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

Authors:

Javier Cortés[1], Véronique Dieras[2], Jungsil Ro[3], Jérôme Barriere[4], Thomas Bachelot[5], Sara Hurvitz[6], Emilie Le Rhun[7], Marc Espie[8], Sung-Bae Kim[9], Andreas Schneeweiss[10], Joo Hyuk Sohn[11], Jean-Marc Nabholtz[12], Pirkko-Liisa Kellokumpu-Lehtinen[13], **Julie Taguchi[14]**, Federico Piacentini[15], Eva Ciruelos[16], Petri Bono[13], Mahmoud Ould-Kaci[17], Flavien Roux[18], Heikki Joensuu[13]